<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="176169">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00802204</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#080861 and 061246</org_study_id>
    <nct_id>NCT00802204</nct_id>
  </id_info>
  <brief_title>Dopamine and Insulin Resistance</brief_title>
  <official_title>Dopamine and Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obese individuals have fewer striatal dopamine type 2 receptors (DRD2) than normal weight
      individuals. Lower DRD2 levels are associated with addiction and a decreased sense of
      pleasure.Obesity is also associated with insulin resistance (poor insulin action).We propose
      that insulin resistance and low DRD2 are associated. Using PET imaging,we aim to determine
      DRD2 binding potential (BP) in the brain is associated with insulin resistance and
      neuroendocrine hormone levels. Obese participants will be compared to lean, gender and age
      similar participants. We also aim to determine the effect of caloric restriction on DRD2 BP
      in obese subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Are fasting neuroendocrine hormones and insulin sensitivity associated with DRD2 receptor binding?</measure>
    <time_frame>Day of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Are certain eating behaviors associated with DRD2 binding?</measure>
    <time_frame>Day of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Does caloric restriction alter DRD2 DP in obese participants?</measure>
    <time_frame>Day of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Obese and lean controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Obese participants and age and gender similar lean controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>PET scan</intervention_name>
    <description>Subjects will undergo a PET scan of the brain using the radioligand,fallypride [18F]. Obese subjects who complete caloric restriction will have repeat scan after diet.</description>
    <arm_group_label>Obese and lean controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Oral glucose tolerance test</intervention_name>
    <description>Subjects will be required to drink a glucose solution; blood samples will be taken over a 5-hour time period</description>
    <arm_group_label>Obese and lean controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>An MRI of the brain and abdomen will be performed prior to PET scan</description>
    <arm_group_label>Obese and lean controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Psychological scales to assess attitudes and behaviors related to eating and quality of life</intervention_name>
    <description>A series of short psychological scales will be administered during the study.</description>
    <arm_group_label>Obese and lean controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Caloric Restriction</intervention_name>
    <description>Obese participants will go a shortterm very low calorie diet</description>
    <arm_group_label>Obese and lean controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 18-60 yrs

          -  obese BMI &gt; 30kg/m2 and Weight less than 350 lbs

          -  lean control BMI 18-25kg/m2

        Exclusion Criteria:

          -  Structured exercise &gt; equivalent to 30mins 5x week of walking times a week

          -  History of Substance Abuse, including but exclusive to alcohol, cocaine, marijuana,
             heroin, nicotine

          -  Current psychiatric disorder or significant h/o disorder

          -  Use or any antidepressants or antipsychotics for last 3-6months or depot
             antipsychotics in the last 12 months

          -  Any condition felt by PI or co-investigators to interfere with ability to complete
             the study

          -  Inability to abstain from alcohol, physical exercise or &gt; 1 cup of coffee or
             equivalent daily for 3 days prior to imaging studies

          -  Significant co-morbidities including atherosclerotic disease, metabolic disease,
             liver or renal insufficiency or abnormality found on MRI

          -  Any condition which would interfere with MRI or PET studies, e.g. claustrophobia,
             cochlear implant, metal fragments in eyes, cardiac pacemaker, neural stimulator,
             tattoos with iron pigment and metallic body inclusions or other metal implanted in
             the body which may interfere with MRI scanning

          -  Subjects on medications determined by PI, ex. sibutramine, frequent benzodiazepines
             or related drugs, which could affect quality of study for last 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia P Dunn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert M Kessler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <lastchanged_date>December 12, 2015</lastchanged_date>
  <firstreceived_date>December 2, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Julia P.Dunn,MD</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Insulin Resistance</keyword>
  <keyword>Neuroendocrine regulation</keyword>
  <keyword>Eating behaviors</keyword>
  <keyword>Dopamine signaling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Dopamine Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
